Singapore - DCH Auriga Singapore is pleased to be the chosen partner by Novartis (Singapore) Pte Ltd to promote and distribute both their pharmaceutical and oncology medicines exclusively in Singapore.

For Novartis’s oncology portfolio, DCH Auriga will be commercialising 10 oncology medicines covering a wide range of indications such as advanced breast cancers, neuroendocrine tumour, kidney and blood cancers, etc.  In addition, DCH Auriga will also be promoting and distributing cardio metabolic, ophthalmology, anti-infectives medicines in the private primary care sector.

Mr. YK Png, Vice-President of DCH Auriga Singapore, “We are pleased to be partnering Novartis Singapore in leveraging on our professional & experience commercial team in bringing essential Oncology & Primary Care medications to the Healthcare Professionals and patients.”

“Our vision is to be Best in Class. Through our patient-centric and omnichannel approach to Healthcare Professionals, coupled with our challenge-accepted attitude, we are able to offer market solutions to principals reaching out to Singapore’s healthcare community effectively and efficiently.”

For any enquiry, please reach out to DCH Auriga Singapore via [email protected]. 

About DCH Auriga

DCH Auriga is an Asian-based integrated market management provider specialising in healthcare. For over 50 years, DCH Auriga helped their partners bring essential pharmaceutical and life science offerings to Asia. Offering both commercial and logistics solutions, Auriga has operations in Hong Kong, Macau, mainland China, Singapore, Thailand, Indonesia, Brunei, Malaysia, Vietnam and the Philippines, distributing more than 1,600 brands at over 50,000 points of sale.